|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.07 EUR | +0.38% |
|
+0.07% | -9.26% |
| 12-10 | Fresenius Medical Care Announces Global Chief Medical Officer and Board Changes | CI |
| 12-10 | MedTech Stocks Diverge Following Exane Report: 'A Split 2026' | DP |
| Capitalization | 11.44B 13.43B 10.68B 10.05B 18.51B 1,216B 20.22B 125B 48.38B 573B 50.38B 49.32B 2,091B | P/E ratio 2025 * |
12.8x | P/E ratio 2026 * | 10.6x |
|---|---|---|---|---|---|
| Enterprise value | 20.53B 24.09B 19.17B 18.04B 33.21B 2,182B 36.28B 224B 86.81B 1,029B 90.41B 88.5B 3,753B | EV / Sales 2025 * |
1.05x | EV / Sales 2026 * | 1x |
| Free-Float |
67.83% | Yield 2025 * |
3.49% | Yield 2026 * | 3.76% |
Last Transcript: Fresenius Medical Care AG
| 1 day | +0.38% | ||
| 1 week | +0.07% | ||
| Current month | -2.86% | ||
| 1 month | -3.75% | ||
| 3 months | -5.72% | ||
| 6 months | -19.65% | ||
| Current year | -9.26% |
| 1 week | 38.98 |  | 40.28 |
| 1 month | 38.98 | | 41.88 |
| Current year | 38.98 | | 54.02 |
| 1 year | 38.98 | | 54.02 |
| 3 years | 28.82 | | 54.02 |
| 5 years | 25.95 | | 71.14 |
| 10 years | 25.95 | | 93.82 |
| Manager | Title | Age | Since |
|---|---|---|---|
Helen Giza
CEO | Chief Executive Officer | 57 | 2022-12-05 |
Martin Fischer
DFI | Director of Finance/CFO | 49 | 2023-09-30 |
Jörg Häring
CMP | Compliance Officer | 55 | 2024-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 58 | 2016-05-11 |
A. Sorensen
BRD | Director/Board Member | 63 | 2021-05-19 |
Michael Sen
CHM | Chairman | 57 | 2023-07-13 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 7.48% | 0 M€ | -.--% | - |
| 0.8% | 0 M€ | -.--% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.38% | +0.07% | -11.60% | +34.92% | 13.43B | |
| +0.50% | -0.40% | +55.38% | +99.72% | 111B | |
| -1.74% | +5.01% | +60.19% | -23.48% | 101B | |
| -1.29% | -0.11% | +36.53% | +82.55% | 31.44B | |
| -0.23% | +2.79% | -14.28% | +17.68% | 24.08B | |
| -0.21% | +2.24% | +13.95% | +16.10% | 21.9B | |
| +0.55% | +0.03% | +16.97% | +22.52% | 20.31B | |
| +1.65% | +2.04% | +63.58% | +77.87% | 18.33B | |
| +0.85% | -5.05% | +47.31% | +350.93% | 17.52B | |
| -0.88% | -3.67% | +19.39% | +73.36% | 13.91B | |
| Average | -0.04% | +0.21% | +28.74% | +75.22% | 37.24B | |
| Weighted average by Cap. | -0.33% | +1.21% | +42.32% | +57.90% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 19.55B 22.95B 18.26B 17.18B 31.64B 2,079B 34.56B 213B 82.69B 980B 86.12B 84.3B 3,575B | 20.15B 23.66B 18.82B 17.71B 32.61B 2,143B 35.62B 220B 85.23B 1,010B 88.76B 86.89B 3,685B |
| Net income | 902M 1.06B 843M 793M 1.46B 95.9B 1.59B 9.83B 3.81B 45.2B 3.97B 3.89B 165B | 1.08B 1.26B 1.01B 946M 1.74B 114B 1.9B 11.73B 4.55B 53.93B 4.74B 4.64B 197B |
| Net Debt | 9.09B 10.67B 8.49B 7.99B 14.7B 966B 16.06B 99.09B 38.43B 455B 40.03B 39.18B 1,662B | 8.69B 10.2B 8.12B 7.64B 14.06B 924B 15.36B 94.73B 36.75B 435B 38.27B 37.46B 1,589B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-12 | 40.13 € | +0.53% | 772,831 |
| 25-12-11 | 39.92 € | -0.05% | 770,923 |
| 25-12-10 | 39.94 € | +1.73% | 873,931 |
| 25-12-09 | 39.26 € | -0.53% | 971,907 |
| 25-12-08 | 39.47 € | -1.42% | 933,210 |
Delayed Quote Xetra, December 12, 2025 at 02:30 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- FME Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition